Suppr超能文献

乳腺癌中雌激素和孕激素受体的现状

Current status of estrogen and progesterone receptors in breast cancer.

作者信息

McGuire W L, Horwitz K B, Pearson O H, Segaloff A

出版信息

Cancer. 1977 Jun;39(6 Suppl):2934-47. doi: 10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p.

Abstract

Breast cancer is often hormone responsive, since growth or regression of tumors can often be modulated by appropriate endocrine manipulations. Estrogen and progesterone appear to be major hormones involved in regulation of breast tumor growth. It has been recently argued that a more accurate marker of hormonal responsiveness might result if an end product of an intact estrogen response system were measured instead of the initial hormone binding step. Progesterone receptor (PgR) has been investigated in this regard since it can be readily measured in human breast tumors and there is clear evidence in experimental breast tumor model systems that PgR is under acute estrogen control. PgR is rarely found in ER- metastatic breast tumors but is present in approximately 59% of ER+ metastatic tumors, especially in those tumors with high levels of ER. Preliminary clinical correlation of ER, PgR and response to endocrine therapy is encouraging. The response rate is significantly higher if the tumor contains both ER and PgR than if the tumor contains ER alone.

摘要

乳腺癌通常对激素有反应,因为肿瘤的生长或消退常常可以通过适当的内分泌干预来调节。雌激素和孕酮似乎是参与调节乳腺肿瘤生长的主要激素。最近有人认为,如果测量完整雌激素反应系统的终产物而不是初始激素结合步骤,可能会得到更准确的激素反应性标志物。鉴于孕酮受体(PgR)可以在人乳腺肿瘤中轻松测量,并且在实验性乳腺肿瘤模型系统中有明确证据表明PgR受雌激素急性调控,因此对此进行了研究。PgR在雌激素受体阴性(ER-)的转移性乳腺肿瘤中很少见,但在约59%的雌激素受体阳性(ER+)转移性肿瘤中存在,尤其是在那些雌激素受体水平高的肿瘤中。雌激素受体、孕酮受体与内分泌治疗反应的初步临床相关性令人鼓舞。如果肿瘤同时含有雌激素受体和孕酮受体,其反应率显著高于仅含有雌激素受体的肿瘤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验